• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Zai Lab Appoints Scott Morrison to its Board of Directors

    10/18/21 7:30:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZLAB alert in real time by email

    SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it has appointed Scott Morrison to its Board of Directors. Mr. Morrison will also serve as a member of the Audit Committee.

    Mr. Morrison has served public and private companies in the life sciences industry since 1980. He was a Partner with Ernst & Young LLP (EY) from 1996 to 2015, serving as its U.S. Life Sciences Leader from 2002 to 2015. During his tenure at EY, he worked on hundreds of public and private financings, M&A transactions, and corporate collaborations. Mr. Morrison retired from EY in December 2015 and now serves on the boards and chairs the Audit Committees of Audentes, Inc. (through its sale to Astellas in January 2020), Corvus Pharmaceuticals, Global Blood Therapeutics (GBT), IDEAYA Biosciences, and Vera Therapeutics. He also serves as a member of the Compensation Committee for GBT and Corvus and is a member of GBT's Commercial Committee.

    Mr. Morrison has also served as a director on several life sciences industry boards, including the Emerging Companies Section (ECS) board of the Biotechnology Innovation Organization (BIO), the Bay Area Biosciences Board (now the California Life Sciences Association, or CLSA), the Life Sciences Foundation, and the Biotechnology Institute. Mr. Morrison was awarded the CLSA Pantheon 2016 Life Sciences Leadership Award. Mr. Morrison holds a B.S. in Business Administration from the Haas School at the University of California, Berkeley.

    "I'm very pleased to have Scott join our board at this important time in Zai Lab's history," said Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab. "We have numerous growth opportunities in front of us, and our executive team and I look forward to partnering with Scott so that his financial expertise can help guide our journey."

    "I'm impressed with the talented team at Zai Lab, its strength in partnering to quickly bring essential medicines to patients, and its productive internal research and development capabilities," commented Morrison. "It's an honor to join the Zai Lab Board, and I look forward to working with Samantha and her team to help Zai Lab realize its vision of becoming a leading global biopharma company."

    About Zai Lab

    Zai Lab (NASDAQ:ZLAB, HKEX: 9688))) is a patient-focused, innovative, research-based, commercial-stage biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders and infectious disease. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies in order to generate a broad pipeline of innovative marketed products and product candidates. We have also built an in-house team with strong product discovery and translational research capabilities and are establishing a pipeline of proprietary product candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.

    Zai Lab Forward-Looking Statements

    This press release contains forward-looking statements including but not limited to statements relating to our strategy and plans; potential of and expectations for our business and pipeline programs; capital allocation and investment strategy; clinical development programs and related clinical trial data; risks and uncertainties associated with drug development and commercialization; regulatory approvals for our pipeline programs and the timing thereof; the potential benefits, safety and efficacy of our collaboration partners' products and investigational therapies; the anticipated benefits and potential of investments, collaborations and business development activities; and our future financial and operating results. These forward-looking statements include, without limitation, statements containing words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "possible," "potential," "will," "would" and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact nor are they guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products; (2) our ability to finance our operations and business initiatives and obtain funding for such activities, (3) our results of clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) the effects of the novel coronavirus (COVID-19) pandemic on our business and general economic, regulatory and political conditions and (6) the risk factors identified in our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission. We anticipate that subsequent events and developments will cause our expectations and assumptions to change and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

    For more information, please contact:

    ZAI LAB CONTACTS:

    Investor Relations: Ron Aldridge / Lina Zhang

    +1 (781) 434-8465 / +86 136 8257 6943

    [email protected] / [email protected]

    Media: Danielle Halstrom / Xiaoyu Chen

    +1 (215) 280-3898 / +86 185 0015 5011

    [email protected] / [email protected]

    Zai Lab Limited



    Primary Logo

    Get the next $ZLAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZLAB

    DatePrice TargetRatingAnalyst
    3/7/2025$55.00Sector Outperform
    Scotiabank
    3/3/2025$29.00 → $36.10Buy → Neutral
    BofA Securities
    12/14/2023$47.50Overweight
    Morgan Stanley
    8/10/2023$70.00Overweight
    Cantor Fitzgerald
    3/2/2022$194.00 → $102.00Outperform
    SVB Leerink
    1/21/2022$64.00Outperform
    Macquarie
    12/15/2021$189.00 → $136.00Overweight
    JP Morgan
    11/11/2021$222.00 → $217.00Buy
    Citigroup
    More analyst ratings

    $ZLAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

      - Clinically meaningful anti-tumor activity of ZL-1310 observed in heavily pretreated population of patients with small cell lung cancer (SCLC) across dose escalation and expansion cohorts - In second-line (2L) SCLC, objective response rate (ORR) was 67% across all dose levels (n=33) and 79% at 1.6 mg/kg dose (n=14) - Median duration of response has not yet been reached, with 29 of 38 responders remaining on study; 27 of 31 patients with stable disease remaining on study, the majority of whom had tumor regressions - ZL-1310 demonstrated a well-tolerated safety profile at target doses of less than 2.0 mg/kg, with Grade ≥3 treatment-related adverse events (TRAEs) of 6%, and no drug disc

      6/2/25 7:00:00 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

      TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients with unresectable, locally advanced pancreatic adenocarcinoma in a Phase 3 trial The OS benefit observed with TTFields therapy is supported by significantly improved quality of life and extended pain-free survival, a key outcome for patients with pancreatic cancer Results from PANOVA-3 accepted as a late-breaking abstract for oral presentation at ASCO and simultaneous publication in the Journal of Clinical Oncology Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) and Novocure (NASDAQ:NVCR)

      5/31/25 3:08:00 PM ET
      $NVCR
      $ZLAB
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Zai Lab Announces Participation in Investor Conferences in June 2025

      Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that members of the Company's senior management team will participate in the following investor conferences in June 2025: Jefferies Global Healthcare Conference Fireside Chat: Wednesday, June 4, 2025, 10:30 a.m. EST Webcast Link: https://wsw.com/webcast/jeff319/zlab/1845848 Location: New York, NY Goldman Sachs 46th Annual Healthcare Conference Time: Monday, June 9, 2025 Location: Miami, FL Scotiabank Third Annual Healthcare Canadian Investor Day Time: Tuesday, June 17, 2025 Location: Toronto, Canada A live webcast of the fireside chat will be available on the Investor Relations page of Zai Lab's website at ir.zailaboratory.

      5/30/25 7:30:00 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZLAB
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Zai Lab Limited

      SCHEDULE 13G/A - Zai Lab Ltd (0001704292) (Subject)

      5/14/25 10:39:54 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Zai Lab Limited

      SCHEDULE 13G/A - Zai Lab Ltd (0001704292) (Subject)

      5/12/25 10:44:44 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Zai Lab Limited

      144 - Zai Lab Ltd (0001704292) (Subject)

      5/9/25 11:35:52 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZLAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairperson & CEO Du Ying exercised 96,389 units of American Depositary Shares at a strike of $0.60 and sold $2,731,507 worth of American Depositary Shares (96,389 units at $28.34) (SEC Form 4)

      4 - Zai Lab Ltd (0001704292) (Issuer)

      5/15/25 4:27:50 PM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Morrison Scott W sold $715,086 worth of American Depositary Shares (23,799 units at $30.05), decreasing direct ownership by 50% to 23,702 units (SEC Form 4)

      4 - Zai Lab Ltd (0001704292) (Issuer)

      5/13/25 4:48:29 PM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairperson & CEO Du Ying exercised 100,000 units of American Depositary Shares at a strike of $0.60 and sold $2,953,308 worth of American Depositary Shares (100,000 units at $29.53) (SEC Form 4)

      4 - Zai Lab Ltd (0001704292) (Issuer)

      5/13/25 4:48:13 PM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZLAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Zai Lab Limited

      SC 13G - Zai Lab Ltd (0001704292) (Subject)

      11/14/24 11:11:39 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zai Lab Limited

      SC 13G/A - Zai Lab Ltd (0001704292) (Subject)

      11/8/24 10:52:38 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Zai Lab Limited (Amendment)

      SC 13G/A - Zai Lab Ltd (0001704292) (Subject)

      6/6/24 9:54:34 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZLAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Smiley Joshua L bought $64,200 worth of American Depositary Shares (3,000 units at $21.40), increasing direct ownership by 10% to 31,684 units (SEC Form 4)

      4 - Zai Lab Ltd (0001704292) (Issuer)

      5/15/24 4:03:12 PM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Smiley Joshua L bought $62,490 worth of American Depositary Shares (3,000 units at $20.83), increasing direct ownership by 15% to 23,527 units (SEC Form 4)

      4 - Zai Lab Ltd (0001704292) (Issuer)

      3/4/24 4:28:34 PM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Smiley Joshua L bought $119,600 worth of American Depositary Shares (4,000 units at $29.90), increasing direct ownership by 24% to 20,527 units (SEC Form 4)

      4 - Zai Lab Ltd (0001704292) (Issuer)

      12/18/23 5:08:48 PM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZLAB
    Leadership Updates

    Live Leadership Updates

    See more
    • Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

        Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume responsibility for all of the Company's Global R&D upon Dr. Reinhart's retirement. "Harald has devoted nearly 50 years to treating patients, first as a physician and later discovering and developing innovative therapies to bring to patients in

      6/11/24 4:05:00 PM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zai Lab Appoints Michel Vounatsos To Its Board of Directors

      SHANGHAI and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that Michel Vounatsos has been appointed to its Board of Directors, effective January 7, 2023. Mr. Vounatsos brings to the Board extensive global leadership and management experience in the biopharmaceutical industry, including more than 25 years of service at leading companies. His expertise includes significant commercial experience in China and worldwide in the areas of primary care and neuroscience. "We are delighted to welcome Michel Vounatsos to the Zai Lab Board of Directors," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Michel has a wealt

      1/9/23 7:30:00 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

      SHANGHAI and CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the appointment of Rafael G. Amado, M.D. as President, Head of Global Oncology Research and Development, effective December 30, 2022. Dr. Amado brings to Zai Lab deep expertise in the field of oncology and significant global biopharmaceutical R&D leadership. "We are pleased to welcome Rafael to our executive leadership team," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Rafael's experience leading worldwide discovery and clinical development for a number of oncolog

      1/3/23 8:30:00 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZLAB
    Financials

    Live finance-specific insights

    See more
    • Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

      - Clinically meaningful anti-tumor activity of ZL-1310 observed in heavily pretreated population of patients with small cell lung cancer (SCLC) across dose escalation and expansion cohorts - In second-line (2L) SCLC, objective response rate (ORR) was 67% across all dose levels (n=33) and 79% at 1.6 mg/kg dose (n=14) - Median duration of response has not yet been reached, with 29 of 38 responders remaining on study; 27 of 31 patients with stable disease remaining on study, the majority of whom had tumor regressions - ZL-1310 demonstrated a well-tolerated safety profile at target doses of less than 2.0 mg/kg, with Grade ≥3 treatment-related adverse events (TRAEs) of 6%, and no drug disc

      6/2/25 7:00:00 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer

      - The Company is on track to initiate a pivotal study for ZL-1310 in small cell lung cancer (SCLC) in 2025 Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZL-1310, the Company's potential first-in-class Delta-like ligand (DLL3) antibody-drug conjugate (ADC), for the treatment of extensive-stage small cell lung cancer (ES-SCLC). ZL-1310, which is being evaluated in an ongoing global Phase 1a/1b clinical trial (NCT06179069), previously received an Orphan Drug designation for SCLC from the FDA. The company will present updated data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meetin

      5/19/25 7:00:00 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates

      – Total revenues grew 22% y-o-y to $106.5 million for the first quarter of 2025; reaffirming full-year 2025 revenue guidance of $560 million to $590 million – Operating loss improved significantly, declining 20% year-over-year to $56.3 million for the first quarter of 2025, and 25% to $37.1 million on an adjusted basis1; on track to achieve profitability1 in the fourth quarter of 2025 – ZL-1310 (DLL3 ADC) is advancing rapidly, with upcoming ASCO 2025 data presentation in ES-SCLC; initiation of registrational study in ES-SCLC expected in the second half of 2025 – AACR 2025 presentations of ZL-6201 (LRRC15 ADC) and ZL-1222 (PD-1/IL-12) underscore the promising potential of Zai Lab's intern

      5/8/25 6:00:00 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZLAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Zai Lab with a new price target

      Scotiabank initiated coverage of Zai Lab with a rating of Sector Outperform and set a new price target of $55.00

      3/7/25 8:00:31 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zai Lab downgraded by BofA Securities with a new price target

      BofA Securities downgraded Zai Lab from Buy to Neutral and set a new price target of $36.10 from $29.00 previously

      3/3/25 7:38:45 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on Zai Lab with a new price target

      Morgan Stanley initiated coverage of Zai Lab with a rating of Overweight and set a new price target of $47.50

      12/14/23 7:54:36 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care